熱門資訊> 正文
EUDA推出基因调节补充剂;上市前股价上涨
2025-08-26 21:43
- Shares of EUDA Health Holdings (NASDAQ:EUDA) rose 10% in the premarket trade on Tuesday after the company announced that it has secured exclusive global distribution rights for a next-generation immune health supplement from Singapore biotech, Chemokine Pte. Ltd.
- Euda Helixé, the supplement, uses epigenetic gene modulation to boost metabolism, energy, skin regeneration, and longevity.
- Initial sales will focus on Singapore, Malaysia, and China, with plans to expand globally.
- Company targets 500,000 unit sales over the next 12 months.
- The product was developed by Prof. Kah Meng Lim, a molecular medicine expert, formerly with Singapore's national R&D agency, A*STAR.
- "The Supplement positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology. " CEO Alfred Lim, said in a statement.
- EUDA +10.48% premarket to $2.95
- Source: Press Release
More on EUDA Health Holdings Limited
- Seeking Alpha’s Quant Rating on EUDA Health Holdings Limited
- Historical earnings data for EUDA Health Holdings Limited
- Financial information for EUDA Health Holdings Limited
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
